Synthesis of (2'S,3'S)-9-(4'-phosphono-4',4'-difluoromethanobutyl)guanine and its enantiomer. Evaluation of the inhibitory activity for purine nucleoside phosphorylase

Tetrahedron

Volumn 53, Issue 33, 1997, Pages 11297-11306

  Yokomatsu, Tsutomu ^a   Sato, Mutsumi ^a   Abe, Hiroshi ^a   Suemune, Kenji ^a   Matsumoto, Keita ^b   Kihara, Taro ^c   Soeda, Shinji ^c   Shimeno, Hiroshi ^c   Shibuya, Shiroshi ^a  

^a TOKYO UNIVERSITY OF PHARMACY AND LIFE SCIENCES   (Japan)

^b TAISHO PHARMACEUTICAL CO LTD   (Japan)

^c FUKUOKA UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

1 (DIETHOXYPHOSPHINYL)DIFLUOROMETHYL 2 HYDROXYMETHYLCYCLOPROPANE; 9 (4' PHOSPHONO 4',4' DIFLUORO 2',3' METHANOBUTYL)GUANINE; 9 (DIFLUOROPHOSPHONOPENTYL)GUANINE DERIVATIVE; GUANINE DERIVATIVE; PURINE NUCLEOSIDE PHOSPHORYLASE; PURINE NUCLEOSIDE PHOSPHORYLASE INHIBITOR; UNCLASSIFIED DRUG;

ARTICLE; CONTROLLED STUDY; DRUG CONFORMATION; DRUG PURITY; DRUG SYNTHESIS; ENANTIOMER; ENZYME INHIBITION; OPTICAL ROTATION; PRIORITY JOURNAL; STEREOCHEMISTRY; TECHNIQUE;

EID: 0030861194     PISSN: 00404020     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0040-4020(97)00704-7     Document Type: Article

References (39)

1. Parks, R. E., Jr.; Agarwal, R. P. In The Enzymes, 3rd ed.; Boyer, P. D., Ed.; Academic Press: New York, 1972; Vol. 7, pp 483-514.
2. Stoeckler, J. D. In Development in Cancer Chemotherapy; Glazer, R. L., Ed.; CRC Press: Boca Raton, 1984; pp35-60.
3. a) Stoeckler, J. D.; Ealick, S. E.; Bugg, C. E.; Parks, R. E. Jr. Fed. Proc., Fed. Am. Soc. Exp. Biol. 1986, 45, 2773.
4. b) Montgomery, J. A. Exp. Opin. Invest. Drugs 1994, 3, 1303.
5. Weibel, M.; Balzarini, J.; Bernhardt, A.; Mamont, P. Biochem. Pharmacol. 1994, 48, 245.
6. a) Nakamura, C. E.; Chu, S.-H.; Stoeckler, J. D.; Park, E. P., Jr. Biochemical Pharmacology 1986, 35, 133.
7. b) Elliott, R. D.; Niwes, S.; Riordan, J. M.; Montogomery, J. A. Sercrist, J. A. Nucleosides and Nucleotides 1992, 11, 97.
8. c) Kelly , J. L.; Linn, J. A.; Mc Lean, E. W.; Tuttle, J. V. J. Med. Chem. 1993, 36, 3455.
9. d) Erion, M. D.; Niwas, S.; Rose, J. D.; Ananthan, S.; Allen, M.; Secrist, J. A.; Babu, Y. S.; Bugg, C. E.; Guida, W. C.; Ealick, S. E.; Montogomery, J. A. J. Med. Chem. 1993, 36, 3771.
10. e) Kelley, J. L.; Mc Lean, E. W.; Crouch, R. C.; Averett, D. R. Tuttle, J. V. J. Med. Chem. 1995, 38, 1005.
11. f) Halazy, S.; Ehrhart, A.; Eggenspiller, A.; Berges-Gross, V.; Danzin, C. Tetrahedron 1996, 52, 177 and references cited therein.
12. Halazy, S.; Ehrhard, A.; Danzin, C. J. Am. Chem. Soc. 1991, 113, 315.
13. Yokomatsu, T.; Suemune, K.; Murano, T.; Shibuya, S. J. Org. Chem. 1996, 67, 7207.
14. Ouerfell, O.; Ishida, M.; Shinozaki, H.; Nakanishi, K.; Ohfune, Y. Synlett 1993, 409. Suda, M. Synthesis 1981, 714 and refernces cited therein.
15. Ouerfell, O.; Ishida, M.; Shinozaki, H.; Nakanishi, K.; Ohfune, Y. Synlett 1993, 409. Suda, M. Synthesis 1981, 714 and refernces cited therein.
16. Lipase AY did not catalyze the transesterification reaction.
17. For the synthesis of chiral alkylphosphonates by lipase-catalyzed transesterification or hydrolysis. a) Heisler, A.; Rabiller, C.; Douillard, R.; Gpalou, N.; Hagele, G.; Levayer, F. Tetrahedron:Asymmetry 1993, 4, 959.
18. b) Li, Y.-F.; Hammerschmidt, F. Tetrahedron:Asymmetry 1993, 4, 109.
19. c) Dresher, M.; Li, Y.-F.; Hammerschmidt, F. Tetrahedron 1995, 51, 4933.
20. d) Yokomatsu, T.; Nakabayashi, N.; Matsumoto, K.; Shibuya, S. Tetrahedron:Asymmetry 1995, 6, 3055.
21. e) Yokomatsu, T.; Sato, M. Shibuya, S. Tetrahedron:Asymmetry 1996, 7, 2743.
22. a) Hirose, Y.; Kariya, K.; Nakanishi, Y.; Kurono, Y.; Achiwa, K. Tetrahedron Lett. 1995, 36, 1063.
23. b) Kojima, Y.; Yokoe, M.; Mase, T. Biosci. Biotech. Biochem. 1994, 58, 1564.
24. Chen, C.-S; Fujimoto, Y.; Girdukas, G.; Sih, C. J. J. Am. Chem. Soc. 1982, 104, 7294.
25. a) Druckhammer, D. G.; Barbas, C. F.; Nozaki, K.; Wong, C-H.; Wong, Y.; Wood, C. Y.; Ciufolini, M. A. J. Org. Chem. 1988, 53, 1607.
26. b) Kazlauskas, R. J. J. Am. Che. Soc. 1989, 111, 4953.
27. c) Hsu, S. H.; Wu, S. S.; Wang, Y. F.; Wong, C. H. Tetrahedron Lett. 1990, 31, 6403.
28. d) Yamazaki, Y.; Morihashi, N.; Hosono, K. Biotechology Lett. 1991, 13, 81.
29. e) Boland, W.; Frobl, C.; Loren, M. Synthesis 1991, 1049.
30. f) Chen, C. S.; Liu, Y. C. J. Org. Chem. 1991, 56, 1966.
31. g) Janssen, A. J. M.; Klunder, A. J. H.; Zwanenburg, Tetrahedron 1991, 47, 7409.
32. h) Garrea, G.; Danieli, B.; Palmisano, G.; Riva, S.; Santagostino, M. Tetrahedron: Asymmetry 1992, 3, 775.
33. i) Brown, S. M.; Davis, S. G.; de Sousa, J. A. A. Tetrahedron: Asymmetry 1993, 4, 813.
34. Theoretically, the transesterification having E = 12.3 should give (-)-6 with 94% ee in 40% yield when the reaction was terminated at the conversion of 60%. However, it was verified that the enzyme lost the activity during a long period to reach the conversion. Therefore, the second kinetic resolution was necessary to give (-)-6 with a high enantiomeric excess.
35. Weissfloch, A. N. E.; Kazlauskas, R. J. J. Org. Chem. 1995, 60, 6959.
36. Purchased from TOYOBO biochemicals.
37. Stoeckler, J. D.; Agarwal, R.; P. Agarwal, K. C.; Parks, R. E., Jr. Methods Enzymol. 1982, 57, 530.
38. Among purine nuclosides, inosine was found to be the best substrate towards the PNP used in this study. The PNP is less reactive towards guanosine and adcnosine than inosine.
39. Hamilton, W. C. Acta Crystallogr. 1965, 78, 502.